CD19 and autoimmune disease: ,29 This likely reflects a function of the overall lower target CD19+ cell number in autoimmune disease as compared with B cell malignancies and the incorporation of 4-1BB co-stimulatory domain, as opposed to a CD28 co-stimulatory domain, in CABA-201,30 factors that also potentially confer a safer profile for the product.